Hebei Medical University Fourth Hospital

This study tests whether a liposomal (encapsulated) form of irinotecan combined with other drugs works better than standard irinotecan for people with metastatic colorectal cancer that has progressed after first-line treatment. About 408 adults aged 18-75 will be randomly assigne…

This study tests a personalized approach for people with HER2-positive breast cancer. About 100 participants will start with standard treatment. If their tumor shrinks less than 40% after two cycles, they will switch to a new drug combination (SHR-A1811 plus pertuzumab) to try to…

This study tests a new drug called befotertinib combined with radiation therapy for people with advanced non-small cell lung cancer that has spread to a few spots (oligometastatic) and has a specific gene change (EGFR mutation). The goal is to see if this combination can delay ca…

This study tests whether adding the drug enlonstobart to short-course radiotherapy and chemotherapy can help shrink tumors more effectively in people with a certain type of advanced rectal cancer (pMMR). About 128 adults will receive either the standard treatment or the new combi…

This study tests the drug olaparib in 30 women with recurrent or metastatic triple-negative breast cancer that has a specific genetic change (BRCA1 promoter methylation) but no BRCA1/2 mutations. The goal is to see if the drug can shrink tumors or slow cancer growth. Participants…

This study tests whether adding radiotherapy to a standard immunotherapy-plus-bevacizumab regimen can shrink liver tumors enough to allow surgery. Sixty adults with unresectable, non-spreading liver cancer will be randomly assigned to receive either the triple combination or the …

This study looks back at medical records of 2,000 people with HER2-positive breast cancer who still had cancer after initial treatment and surgery. Researchers compare two different drug combinations given after surgery to see which one helps prevent the cancer from coming back. …